Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying ...

A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely ...

Before market open, Wave presented interim data from a phase 1 clinical trial of its WVE-007 weight loss drug. The treatment was found to reduce total body fat in its recipients by 4.5% over the three ...

Equities research analysts at Citigroup started coverage on shares of WAVE Life Sciences (NASDAQ:WVE – Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The firm set a “buy” ...

It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 ...